Common antidepressant offers hope for people looking to reduce methamphetamine use
In April, NDARC released the results of the landmark Tina Trial, a double-blind, placebo-controlled randomised clinical trial of 344 adults with methamphetamine use disorder.
The results showed that adults who took mirtazapine – a generic antidepressant – were significantly more likely to reduce their methamphetamine use compared to those who were in the placebo group. The full paper is available in JAMA Psychiatry.
The study is important as there are currently no approved medications available for people with methamphetamine use disorder, which is a global challenge with 7.4 million people in the world who are dependent.
Chief Investigator, NDARC’s Professor Rebecca McKetin co-authored a piece in The Conversation to share the results with a broader, general audience.
You can read the NDARC media release here.
Professor McKetin shared her reflections and insights on conducting the Tina Trial on the NDARC blog, the post is available here.
